Invizius – the Edinburgh-based biotech company developing breakthrough treatments for patients on dialysis – has raised £950,000 in a funding round led by Mercia Ventures and supported by Calculus Capital, Syensqo, the University of Edinburgh’s Old College Capital and Scottish Enterprise.
The latest investment will enable the company to prepare for the next stage of clinical trials of its H-Guard product and comes in the run-up to a Series B investment round early next year….
Read More…